Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson
The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.
You may also be interested in...
Prohibition by Health and Human Services Department Office of Civil Rights would apply to use of such metrics in determining formulary access but not to use in ‘academic’ research.
The brand drug industry’s success in tackling COVID-19 followed by swift political loss with the Inflation Reduction Act is in part due to the public’s continued knowledge gaps about the medical innovation ecosystem, outgoing PhRMA VP Jenny Bryant tells Pink Sheet in an interview.
Drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.